

# Richard A Lake

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6111700/publications.pdf>

Version: 2024-02-01

35  
papers

2,294  
citations

361413

20  
h-index

361022

35  
g-index

35  
all docs

35  
docs citations

35  
times ranked

4224  
citing authors

#	ARTICLE	IF	CITATIONS
1	Retinoic Acid Induces an IFN-Driven Inflammatory Tumour Microenvironment, Sensitizing to Immune Checkpoint Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 849793.	2.8	7
2	Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	3
3	A phase 1b clinical trial optimizing regulatory T cell depletion in combination with platinum-based chemotherapy in thoracic cancers. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 465-474.	2.4	1
4	Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 584423.	4.8	39
5	Bilateral murine tumor models for characterizing the response to immune checkpoint blockade. <i>Nature Protocols</i> , 2020, 15, 1628-1648.	12.0	19
6	Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 223.	4.8	54
7	Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	147
8	Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment. <i>Oncolmmunology</i> , 2019, 8, e1641390.	4.6	22
9	Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors. <i>BMC Research Notes</i> , 2018, 11, 864.	1.4	7
10	Combination immune checkpoint blockade as an effective therapy for mesothelioma. <i>Oncolmmunology</i> , 2018, 7, e1494111.	4.6	37
11	Transient Treg depletion enhances therapeutic anti-cancer vaccination. <i>Immunity, Inflammation and Disease</i> , 2017, 5, 16-28.	2.7	33
12	Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 264-272.	46.4	204
13	Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters. <i>BMC Cancer</i> , 2017, 17, 417.	2.6	8
14	A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice. <i>BMC Cancer</i> , 2017, 17, 684.	2.6	125
15	Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response. <i>Oncotarget</i> , 2017, 8, 19803-19813.	1.8	30
16	A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis. <i>Journal of Thoracic Oncology</i> , 2016, 11, 573-582.	1.1	126
17	Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies. <i>Oncolmmunology</i> , 2016, 5, e1066062.	4.6	55
18	PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors. <i>Lung Cancer</i> , 2016, 93, 9-16.	2.0	27

#	ARTICLE	IF	CITATIONS
19	Chemotherapy and immunotherapy: mapping the road ahead. <i>Current Opinion in Immunology</i> , 2016, 39, 23-29.	5.5	105
20	Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations. <i>Scientific Reports</i> , 2015, 5, 12298.	3.3	63
21	Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma. <i>BMC Cancer</i> , 2015, 15, 983.	2.6	13
22	Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy. <i>European Journal of Immunology</i> , 2015, 45, 49-59.	2.9	64
23	Restoration of defective cross-presentation in tumors by gemcitabine. <i>Oncolmmunology</i> , 2015, 4, e1005501.	4.6	16
24	Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen. <i>Oncolmmunology</i> , 2015, 4, e1011492.	4.6	26
25	Chemotherapy Enhances Cross-Presentation of Nuclear Tumor Antigens. <i>PLoS ONE</i> , 2014, 9, e107894.	2.5	20
26	Combining chemotherapy and checkpoint blockade in thoracic cancer: how to proceed?. <i>Lung Cancer Management</i> , 2014, 3, 443-457.	1.5	8
27	Effect of NSAIDS and COX-2 inhibitors on the incidence and severity of asbestos-induced malignant mesothelioma: Evidence from an animal model and a human cohort. <i>Lung Cancer</i> , 2014, 86, 29-34.	2.0	13
28	Statins Do Not Alter the Incidence of Mesothelioma in Asbestos Exposed Mice or Humans. <i>PLoS ONE</i> , 2014, 9, e103025.	2.5	6
29	Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity. <i>PLoS ONE</i> , 2013, 8, e61895.	2.5	129
30	Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1219-1228.	4.2	127
31	Immunotherapy and chemotherapy – a practical partnership. <i>Nature Reviews Cancer</i> , 2005, 5, 397-405.	28.4	610
32	Altered superantigenic ligands demonstrate the quantitative nature of T-cell activation. <i>Immunology and Cell Biology</i> , 2000, 78, 623-632.	2.3	1
33	Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generation. <i>Cancer Gene Therapy</i> , 2000, 7, 663-670.	4.6	113
34	New chemotherapeutics in malignant mesothelioma: effects on cell growth and IL-6 production. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 45, 502-508.	2.3	15
35	Cross-presentation of tumour antigens: Evaluation of threshold, duration, distribution and regulation. <i>Immunology and Cell Biology</i> , 1999, 77, 552-558.	2.3	21